Leadership & Pay ·
TELA Bio reported second quarter 2026 revenue of $19.3 million, a 4% decline from the prior year period, driven by…
TELATELA Bio, Inc.
TELA Bio reported second quarter 2026 revenue of $19.3 million, a 4% decline from the prior year period, driven by lower OviTex PRS volumes and price headwinds despite international growth of 26%. The company announced the appointment of Heather Getz as Chief Executive Officer effective August 4, 2026. Consequently, TELA Bio withdrew its full-year 2026 revenue guidance to reassess strategic direction while implementing cost reductions to extend cash runway. Cash and equivalents stood at $30.4 million on June 30, 2026. The company operates in the medical technology industry, providing soft-tissue reconstruction solutions.